E-viri
Recenzirano
Odprti dostop
-
Mathelin, Carole; Ame, Shanti; Anyanwu, Stanley; Avisar, Eli; Boubnider, Wahib Mohcen; Breitling, Katrin; Anie, Hannah Ayettey; Conceição, José Carlos; Dupont, Veronique; Elder, Elisabeth; Elfgen, Constanze; Elonge, Tony; Iglesias, Edelmiro; Imoto, Shigeru; Ioannidou-Mouzaka, Lydia; Kappos, Elisabeth A; Kaufmann, Martin; Knauer, Michael; Luzuy, Franck; Margaritoni, Marko; Mbodj, Mamadou; Mundinger, Alexander; Orda, Ruben; Ostapenko, Valerijus; Özbaş, Serdar; Özmen, Vahit; Pagani, Olivia; Pieńkowski, Tadeusz; Schneebaum, Schlomo; Shmalts, Ekaterina; Selim, Ashraf; Pavel, Zotov; Lodi, Massimo; Maghales-Costa, Maurício
European journal of breast health, 04/2021, Letnik: 17, Številka: 2Journal Article
In early 2020, the spread of coronavirus disease-2019 (COVID-19) led the World Health Organization to declare this disease a pandemic. Initial epidemiological data showed that patients with cancer were at high risk of developing severe forms of COVID-19. National scientific societies published recommendations modifying the patients' breast cancer (BC) management to preserve, in theory, quality oncologic care, avoiding the increased risk of contamination. The Senology International Society (SIS) decided to take an inventory of the actions taken worldwide. This study investigates COVID-19-related changes concerning BC management and analyzes the will to maintain them after the pandemic, evaluating their oncological safety consequences. SIS network members participated in an online survey using a questionnaire (Microsoft Forms) from June 15 to July 31 , 2020. Forty-five responses from 24 countries showed that screening programs had been suspended (68%); magnetic resonance imagines were postponed (73%); telemedicine was preferred when possible (71%). Surgeries were postponed: reconstructive (77%), for benign diseases (84%), and in patients with significant comorbidities (66%). Chemotherapy and radiotherapy protocols had been adapted in 28% of patients in both. Exception for telemedicine (34%), these changes in practice should not be continued. The SIS survey showed significant changes in BC's diagnosis and treatment during the first wave of the COVID-19 pandemic, but most of these changes should not be maintained. Indeed, women have fewer severe forms of COVID-19 and are less likely to die than men. The risk of dying from COVID-19 is more related to the presence of comorbidities and age than to BC. Stopping screening and delaying treatment leads to more advanced stages of BC. Only women aged over 65 with BC under treatment and comorbidities require adaptation of their cancer management.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.